WAVEMAN · COMPANY

CELU · Celularity Inc

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

CELU

Name: Celularity Inc (CELU) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Celularity Inc

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001752828

ACTIVIST 13D☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

-51.0%

XBRL, annual

NET MARGIN

-345.4%

CONVERSIONS · 180D

codes C/M, not in net · $0 priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

19 funds added or opened last quarter

below 71% of Pharma & Biotech

REVENUE

-51.0% year over year

below 84% of Pharma & Biotech

MARGIN

-345.4% net margin

below 79% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

1.4% of shares outstanding short · 7.7 days to cover · settled 2026-07-31

below 69% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

PHILP & DANIELE BARACH FAMILY TRUST disclosed a 5%+ stake (9.56%) in the last six months.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -34.1%

-34.1%12M

13D/G STAKE

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

An activist crossed the 5% line with declared intent.

The record shows 19 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for Celularity Inc in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Genting Berhad

—

BUY

2024-01-12

21,410,983.0

$5.4M

Hariri Robert J

Chief Executive Officer

BUY

2023-10-05

3,050,427.0

$488.1K

Hariri Robert J

Chief Executive Officer

BUY

2023-10-05

6,307,158.0

$1.0M

Sorrento Therapeutics, Inc.

—

SELL

2023-10-05

6,307,158.0

Hariri Robert J

Chief Executive Officer

BUY

2023-09-29

9,064,539.0

$1.5M

9 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 4 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

C V STARR & CO INC

764,069.0 sh

$1.6M

VANGUARD CAPITAL MANAGEMENT LLC

621,105.0 sh

$371.4K

GEODE CAPITAL MANAGEMENT, LLC

167,150.0 sh

$100.0K

CITADEL ADVISORS LLC

99,054.0 sh

$59.2K

VANGUARD FIDUCIARY TRUST CO

79,874.0 sh

$47.8K

5%+ owners

13D = intent to influence · 13G = passive

PHILP & DANIELE BARACH FAMILY TRUST

ACTIVIST 13D · 2026-04-03

9.56%

PHILIP A. BARACH

ACTIVIST 13D · 2026-04-03

9.56%

DANIELE BARACH

ACTIVIST 13D · 2026-04-03

9.56%

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

iShares Micro-Cap ETF

$53.2K POSITION · AS OF 2026-03-31

0.0%

1290 VT Micro Cap Portfolio

$2.9K POSITION · AS OF 2026-03-31

0.0%

VANGUARD EXTENDED MARKET INDEX FUND

$220.9K POSITION · AS OF 2026-03-31

0.0%

Fidelity Extended Market Index Fund

$105.9K POSITION · AS OF 2026-02-28

0.0%

Fidelity Nasdaq Composite Index Fund

$10.4K POSITION · AS OF 2026-02-28

0.0%

VANGUARD TOTAL STOCK MARKET INDEX FUND

$605.2K POSITION · AS OF 2026-03-31

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 9 registered trials, 0 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

0 ACTIVE

Phase 2

0 ACTIVE

Multi-phase

0 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$26.6M	$54.2M	$22.8M	$18.0M
GROSS PROFIT	—	—	$6.8M	$-1.7M
OPERATING INCOME	$-61.3M	$-38.4M	$-192.3M	$-25.6M
NET INCOME	$-91.7M	$-57.9M	$-196.3M	$14.2M
EPS (DILUTED)	-3.59	-2.64	-11.02	0.95
OPERATING CASH FLOW	$-13.3M	$-6.4M	$-38.7M	$-137.9M
CASH	$6.2M	$738.0K	$227.0K	$14.0M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE